SCHEMBL9900767

SCHEMBL9900767

Cc1cn([C@H]2CC(O)[C@@H](COP(=O)(O)O)O2)c(=O)nc1N

nearest known ligand 0.63

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.55
TYMS P04818 2/20 0.53
TK1 P04183 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18180945 1.00 POLB (0.55) POLBTYMSTK1
SCHEMBL502418 1.00 POLB (0.55) POLBTYMSTK1
SCHEMBL13224513 0.94 POLB (0.53) POLBTYMS
SCHEMBL13899894 0.94 POLB (0.53) POLBTYMS
SCHEMBL16416278 0.93 POLB (0.52) POLBTYMS
SCHEMBL19681270 0.93 POLB (0.52) POLBTYMS
SCHEMBL14661236 0.92 POLB (0.56) POLB
SCHEMBL14661232 0.92 POLB (0.56) POLB
SCHEMBL16038405 0.92 POLB (0.51) POLBTYMS
SCHEMBL20906736 0.90 POLG (0.55) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125749-A1 HAIRPIN LOOP METHOD FOR DOUBLE STRAND POLYNUCLEOTIDE SEQUENCING USING TRANSMEMBRANE PORES OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2026-05-07 US disclosed
US-12595509-B2 Synthetic nucleic acid spike-ins KARIUS, INC. (US) 2026-04-07 US disclosed
US-20260072019-A1 METHOD OF DETERMINING THE PRESENCE OR ABSENCE OF A TARGET ANALYTE COMPRISING USING A REPORTER POLYNUCLEOTIDE AND A TRANSMEMBRANE PORE OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2026-03-12 US disclosed
US-12553085-B2 Sequencing kit OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2026-02-17 US disclosed
US-20260043809-A1 AFFINITY CAPTURE REAGENTS FOR MASS SPECTROMETRY UNIV OXFORD INNOVATION LTD (GB) 2026-02-12 US disclosed
US-20260028379-A1 MUTANT PORE OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2026-01-29 US disclosed
US-12509721-B2 Methods and systems for characterizing analytes using nanopores OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2025-12-30 US disclosed
EP-4665753-A1 ARMOURED REGULATORY T CELL King's College London (GB) 2025-12-24 EP disclosed
US-20250361502-A1 Promoters And Compositions UNIV OXFORD INNOVATION LTD (GB) 2025-11-27 US disclosed
EP-3802877-B1 METHOD OXFORD NANOPORE TECH PLC (GB) 2025-11-05 EP disclosed
WO-2014170661-A1 STRAIN OF DEFORMED WING VIRUS (DWV) THE UNIVERSITY OF WARWICK (GB) 2014-10-23 WO disclosed
WO-2014102539-A1 DELIVERY METHOD USING MESOPOROUS SILICA NANOPARTICLES ISIS INNOVATION LIMITED (GB) 2014-07-03 WO disclosed
EP-2737084-A1 HAIRPIN LOOP METHOD FOR DOUBLE STRAND POLYNUCLEOTIDE SEQUENCING USING TRANSMEMBRANE PORES Oxford Nanopore Technologies Limited (GB) 2014-06-04 EP disclosed
WO-2014072703-A1 QUADRUPLEX METHOD OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) 2014-05-15 WO disclosed
WO-2014064444-A1 DROPLET INTERFACES OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) 2014-05-01 WO disclosed
WO-2013153359-A1 MUTANT LYSENIN PORES OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) 2013-10-17 WO disclosed
WO-2013121201-A1 APTAMER METHOD OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) 2013-08-22 WO disclosed
WO-2013121224-A1 ANALYSIS OF MEASUREMENTS OF A POLYMER OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) 2013-08-22 WO disclosed
WO-2013014451-A1 HAIRPIN LOOP METHOD FOR DOUBLE STRAND POLYNUCLEOTIDE SEQUENCING USING TRANSMEMBRANE PORES OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) 2013-01-31 WO disclosed
WO-2012078288-A2 METHODS OF DETERMINING RISK OF ADVERSE OUTCOMES IN ACUTE MYELOID LEUKEMIA WASHINGTON UNIVERSITY (US) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260072019-A1 METHOD OF DETERMINING THE PRESENCE OR ABSENCE OF A TARGET ANALYTE COMPRISING USING A REPORTER POLYNUCLEOTIDE AND A TRANSMEMBRANE PORE NUP210, EPCAM, PHAX POLB 1826/4885TYMS 2007/4885TK1 1669/4885
US-12509721-B2 Methods and systems for characterizing analytes using nanopores DNA2, MTREX, DDX21 POLB 48/4885TYMS 997/4885TK1 515/4885
US-20260043809-A1 AFFINITY CAPTURE REAGENTS FOR MASS SPECTROMETRY DDX6, DDX1, DDB1 POLB 647/4885TYMS 2902/4885TK1 592/4885
US-12553085-B2 Sequencing kit PHAX, TIA1, POLM POLB 684/4885TYMS 1750/4885TK1 653/4885
US-20260125749-A1 HAIRPIN LOOP METHOD FOR DOUBLE STRAND POLYNUCLEOTIDE SEQUENCING USING TRANSMEMBRANE PORES POLRMT, PITPNB, NUP205 POLB 81/4885TYMS 1917/4885TK1 2532/4885
US-20260028379-A1 MUTANT PORE PTMS, NUP50, NUP205 POLB 2195/4885TYMS 3991/4885TK1 3314/4885
US-12595509-B2 Synthetic nucleic acid spike-ins SPOUT1, NOP2, METTL16 POLB 594/4885TYMS 1196/4885TK1 2054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.